Search
Panobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalPanobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. … The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted
Synonyms: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-PROPENAMIDE, N-HYDROXY-3-(4-(((2-(2-METHYL-1H-INDOL-3-YL)ETHYL)AMINO)METHYL)PHENYL)-, (2E)-Abiraterone
go.drugbank.com/drugs/DB05812ApprovedInvestigationalIt is used to treat metastatic castration-resistant prostate cancer, hormone-sensitive high-risk metastatic prostate cancer. … [A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April,[A260880] July,[L47745] and September 2011,[A260880] respectively.
Calcifediol
go.drugbank.com/drugs/DB00146ApprovedInvestigationalNutraceuticalThe major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores. … It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties.
Synonyms: (3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol, (3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diolInternational brands: De KaiRozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigational[A260182] Generalized myasthenia gravis is characterized by the formation of IgG antibodies against the nicotinic acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK). … Rozanolixizumab is a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P) targeting the immunoglobulin G (IgG).
Categories: Neonatal Fc Receptor BlockerTelaprevir
go.drugbank.com/drugs/DB05521ApprovedWithdrawnThe substitutions of the enzyme's catalytic triad consisting of H58, D82, and S139 are also likely to alter the affinity of the drug for NS3/4A or the activity of the enzyme itself. … Telaprevir, [DB00811], [DB00008], and [DB00022] were used with the intent to cure, or achieve a sustained virologic response (SVR), after 12 weeks of daily administration of the combination therapy followed
Propanoic acid
go.drugbank.com/drugs/DB03766ApprovedInvestigationalVet approvedWithdrawnSodium propionate was previously approved in Canada as an active ingredient in Amino-Cerv (used to treat inflammation or injury of the cervix). … Sodium propionate is the sodium salt of propionic acid that exists as colorless, transparent crystals or a granular crystalline powder.
Carprofen
go.drugbank.com/drugs/DB00821ApprovedVet approvedWithdrawnIt was generally well tolerated, with the majority of adverse effects being mild, such as gastro-intestinal pain and nausea, similar to those recorded with aspirin and other non-steroidal anti-inflammatory … Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians as a supportive treatment for the relief of arthritic symptoms in geriatric dogs.
Niraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigational[A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. … [L43747] On December 12, 2025, the FDA expanded niraparib and abiraterone acetate (AKEEGA) with prednisone for the treatment of patients with BRCA2-mutated metastatic castration-sensitive prostate cancer
Reviparin
go.drugbank.com/drugs/DB09259ApprovedReviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin. … [A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[L1469]
Products: CLIVARIN 5726 IE A XA/MLVestronidase alfa
go.drugbank.com/drugs/DB12366ApprovedInvestigationalMPS VII is a progressive condition that affects most tissues and organs due to the lack of a lysosomal enzyme called beta-glucuronidase, leading to buildup of toxic metabolites. … In clinical trials, vestronidase alfa treatment demonstrated improvement and stabilization in motor symptoms by increasing the patients' ability to walk longer distances in comparison to treatment with